Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study

Clopidogrel is an oral antiplatelet prodrug, the majority of which is hydrolyzed to an inactive metabolite by hepatic carboxylesterase 1 (CES1). Most angiotensin‐converting enzyme inhibitors (ACEIs) are also metabolized by this enzyme. We examined the effects of ACEIs on clopidogrel bioactivation in...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2014-12, Vol.96 (6), p.713-722
Main Authors: Kristensen, K E, Zhu, H-J, Wang, X, Gislason, G H, Torp-Pedersen, C, Rasmussen, H B, Markowitz, J S, Hansen, P R
Format: Article
Language:English
Subjects:
Aged
Angiotensin-Converting Enzyme Inhibitors - pharmacology
Biotransformation
Carboxylic Ester Hydrolases - physiology
Drug Interactions
Female
Hemorrhage - chemically induced
Humans
Male
Middle Aged
Myocardial Infarction - drug therapy
Platelet Aggregation Inhibitors - pharmacokinetics
Risk
Ticlopidine - adverse effects
Ticlopidine - analogs & derivatives
Ticlopidine - pharmacokinetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4903-99c8af94fb7135213eeee69b48b6985a57d26b334b813e7eaccbdc91b695f2da3
cites cdi_FETCH-LOGICAL-c4903-99c8af94fb7135213eeee69b48b6985a57d26b334b813e7eaccbdc91b695f2da3
container_end_page 722
container_issue 6
container_start_page 713
container_title Clinical pharmacology and therapeutics
container_volume 96
creator Kristensen, K E
Zhu, H-J
Wang, X
Gislason, G H
Torp-Pedersen, C
Rasmussen, H B
Markowitz, J S
Hansen, P R
description Clopidogrel is an oral antiplatelet prodrug, the majority of which is hydrolyzed to an inactive metabolite by hepatic carboxylesterase 1 (CES1). Most angiotensin‐converting enzyme inhibitors (ACEIs) are also metabolized by this enzyme. We examined the effects of ACEIs on clopidogrel bioactivation in vitro and linked the results with a pharmacoepidemiological study. In vitro, ACEIs inhibited CES1‐mediated hydrolysis of a model substrate, and trandolapril and enalapril increased formation of clopidogrel active metabolite. In 70,934 patients with myocardial infarction, hazard ratios for clinically significant bleeding in ACEI‐treated patients cotreated with or without clopidogrel were 1.10 (95% confidence interval (CI): 0.97–1.25, P = 0.124) and 0.90 (95% CI: 0.81–0.99, P = 0.025), respectively, as compared with patients who did not receive ACEIs. This difference was statistically significant (P = 0.002). We conclude that cotreatment with selected ACEIs and clopidogrel may increase the risk of bleeding. Combination of in vitro and pharmacoepidemiological studies may be a useful paradigm for assessment of drug–drug interactions. Clinical Pharmacology & Therapeutics (2014); 96 6, 713–722. doi:10.1038/clpt.2014.183
doi_str_mv 10.1038/clpt.2014.183
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1634498738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1634498738</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4903-99c8af94fb7135213eeee69b48b6985a57d26b334b813e7eaccbdc91b695f2da3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EokvhyBX5yCVLbOefuW2j0lZaygqCirhYjjPZmmbt1PYWwifiY-Jolx6xRrJG7zfP1jyEXpN0SVJWvVPDGJY0JdmSVOwJWpCc0aTIWf4ULdI05QmnrDhBL7z_EduMV9VzdEJzSmlB0wX6Uw921J3dOhjwmbZSBf0gg7YGS9Phz9rfYdvjswGg02aLtcGbKIMJHtc2OJABOnyjwy1ema22AYzXJqmteQAX5olz83vaAb4yt7rVwTqPV30Ahz9OVknXaTlErZdOzY--xyu8cdb2SaxoomAM-EvYd9NL9KyXg4dXx_sUff1w3tSXyfrTxVW9Wicq4ylLOFeV7HnWtyVhOSUM4il4m1Vtwatc5mVHi5axrK2iVoJUqu0UJ1HNe9pJdoreHnxHZ-_34IPYaa9gGKQBu_eCFCyLWyxZFdHkgCpnvXfQi9HpnXSTIKmYwxFzOGIOR8RwIv_maL1vd9A90v_SiAA_AD_1ANP_3US9aer1ppn7g_nxM9oH-PU4K92dKEpW5uLm-kJc0m_X7HtDRMP-AiWBrzs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1634498738</pqid></control><display><type>article</type><title>Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Kristensen, K E ; Zhu, H-J ; Wang, X ; Gislason, G H ; Torp-Pedersen, C ; Rasmussen, H B ; Markowitz, J S ; Hansen, P R</creator><creatorcontrib>Kristensen, K E ; Zhu, H-J ; Wang, X ; Gislason, G H ; Torp-Pedersen, C ; Rasmussen, H B ; Markowitz, J S ; Hansen, P R</creatorcontrib><description>Clopidogrel is an oral antiplatelet prodrug, the majority of which is hydrolyzed to an inactive metabolite by hepatic carboxylesterase 1 (CES1). Most angiotensin‐converting enzyme inhibitors (ACEIs) are also metabolized by this enzyme. We examined the effects of ACEIs on clopidogrel bioactivation in vitro and linked the results with a pharmacoepidemiological study. In vitro, ACEIs inhibited CES1‐mediated hydrolysis of a model substrate, and trandolapril and enalapril increased formation of clopidogrel active metabolite. In 70,934 patients with myocardial infarction, hazard ratios for clinically significant bleeding in ACEI‐treated patients cotreated with or without clopidogrel were 1.10 (95% confidence interval (CI): 0.97–1.25, P = 0.124) and 0.90 (95% CI: 0.81–0.99, P = 0.025), respectively, as compared with patients who did not receive ACEIs. This difference was statistically significant (P = 0.002). We conclude that cotreatment with selected ACEIs and clopidogrel may increase the risk of bleeding. Combination of in vitro and pharmacoepidemiological studies may be a useful paradigm for assessment of drug–drug interactions. Clinical Pharmacology &amp; Therapeutics (2014); 96 6, 713–722. doi:10.1038/clpt.2014.183</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/clpt.2014.183</identifier><identifier>PMID: 25222620</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Aged ; Angiotensin-Converting Enzyme Inhibitors - pharmacology ; Biotransformation ; Carboxylic Ester Hydrolases - physiology ; Drug Interactions ; Female ; Hemorrhage - chemically induced ; Humans ; Male ; Middle Aged ; Myocardial Infarction - drug therapy ; Platelet Aggregation Inhibitors - pharmacokinetics ; Risk ; Ticlopidine - adverse effects ; Ticlopidine - analogs &amp; derivatives ; Ticlopidine - pharmacokinetics</subject><ispartof>Clinical pharmacology and therapeutics, 2014-12, Vol.96 (6), p.713-722</ispartof><rights>2014 American Society for Clinical Pharmacology and Therapeutics</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4903-99c8af94fb7135213eeee69b48b6985a57d26b334b813e7eaccbdc91b695f2da3</citedby><cites>FETCH-LOGICAL-c4903-99c8af94fb7135213eeee69b48b6985a57d26b334b813e7eaccbdc91b695f2da3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25222620$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kristensen, K E</creatorcontrib><creatorcontrib>Zhu, H-J</creatorcontrib><creatorcontrib>Wang, X</creatorcontrib><creatorcontrib>Gislason, G H</creatorcontrib><creatorcontrib>Torp-Pedersen, C</creatorcontrib><creatorcontrib>Rasmussen, H B</creatorcontrib><creatorcontrib>Markowitz, J S</creatorcontrib><creatorcontrib>Hansen, P R</creatorcontrib><title>Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clinical Pharmacology &amp; Therapeutics</addtitle><description>Clopidogrel is an oral antiplatelet prodrug, the majority of which is hydrolyzed to an inactive metabolite by hepatic carboxylesterase 1 (CES1). Most angiotensin‐converting enzyme inhibitors (ACEIs) are also metabolized by this enzyme. We examined the effects of ACEIs on clopidogrel bioactivation in vitro and linked the results with a pharmacoepidemiological study. In vitro, ACEIs inhibited CES1‐mediated hydrolysis of a model substrate, and trandolapril and enalapril increased formation of clopidogrel active metabolite. In 70,934 patients with myocardial infarction, hazard ratios for clinically significant bleeding in ACEI‐treated patients cotreated with or without clopidogrel were 1.10 (95% confidence interval (CI): 0.97–1.25, P = 0.124) and 0.90 (95% CI: 0.81–0.99, P = 0.025), respectively, as compared with patients who did not receive ACEIs. This difference was statistically significant (P = 0.002). We conclude that cotreatment with selected ACEIs and clopidogrel may increase the risk of bleeding. Combination of in vitro and pharmacoepidemiological studies may be a useful paradigm for assessment of drug–drug interactions. Clinical Pharmacology &amp; Therapeutics (2014); 96 6, 713–722. doi:10.1038/clpt.2014.183</description><subject>Aged</subject><subject>Angiotensin-Converting Enzyme Inhibitors - pharmacology</subject><subject>Biotransformation</subject><subject>Carboxylic Ester Hydrolases - physiology</subject><subject>Drug Interactions</subject><subject>Female</subject><subject>Hemorrhage - chemically induced</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Platelet Aggregation Inhibitors - pharmacokinetics</subject><subject>Risk</subject><subject>Ticlopidine - adverse effects</subject><subject>Ticlopidine - analogs &amp; derivatives</subject><subject>Ticlopidine - pharmacokinetics</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9kU9v1DAQxS0EokvhyBX5yCVLbOefuW2j0lZaygqCirhYjjPZmmbt1PYWwifiY-Jolx6xRrJG7zfP1jyEXpN0SVJWvVPDGJY0JdmSVOwJWpCc0aTIWf4ULdI05QmnrDhBL7z_EduMV9VzdEJzSmlB0wX6Uw921J3dOhjwmbZSBf0gg7YGS9Phz9rfYdvjswGg02aLtcGbKIMJHtc2OJABOnyjwy1ema22AYzXJqmteQAX5olz83vaAb4yt7rVwTqPV30Ahz9OVknXaTlErZdOzY--xyu8cdb2SaxoomAM-EvYd9NL9KyXg4dXx_sUff1w3tSXyfrTxVW9Wicq4ylLOFeV7HnWtyVhOSUM4il4m1Vtwatc5mVHi5axrK2iVoJUqu0UJ1HNe9pJdoreHnxHZ-_34IPYaa9gGKQBu_eCFCyLWyxZFdHkgCpnvXfQi9HpnXSTIKmYwxFzOGIOR8RwIv_maL1vd9A90v_SiAA_AD_1ANP_3US9aer1ppn7g_nxM9oH-PU4K92dKEpW5uLm-kJc0m_X7HtDRMP-AiWBrzs</recordid><startdate>201412</startdate><enddate>201412</enddate><creator>Kristensen, K E</creator><creator>Zhu, H-J</creator><creator>Wang, X</creator><creator>Gislason, G H</creator><creator>Torp-Pedersen, C</creator><creator>Rasmussen, H B</creator><creator>Markowitz, J S</creator><creator>Hansen, P R</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201412</creationdate><title>Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study</title><author>Kristensen, K E ; Zhu, H-J ; Wang, X ; Gislason, G H ; Torp-Pedersen, C ; Rasmussen, H B ; Markowitz, J S ; Hansen, P R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4903-99c8af94fb7135213eeee69b48b6985a57d26b334b813e7eaccbdc91b695f2da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Angiotensin-Converting Enzyme Inhibitors - pharmacology</topic><topic>Biotransformation</topic><topic>Carboxylic Ester Hydrolases - physiology</topic><topic>Drug Interactions</topic><topic>Female</topic><topic>Hemorrhage - chemically induced</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Platelet Aggregation Inhibitors - pharmacokinetics</topic><topic>Risk</topic><topic>Ticlopidine - adverse effects</topic><topic>Ticlopidine - analogs &amp; derivatives</topic><topic>Ticlopidine - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kristensen, K E</creatorcontrib><creatorcontrib>Zhu, H-J</creatorcontrib><creatorcontrib>Wang, X</creatorcontrib><creatorcontrib>Gislason, G H</creatorcontrib><creatorcontrib>Torp-Pedersen, C</creatorcontrib><creatorcontrib>Rasmussen, H B</creatorcontrib><creatorcontrib>Markowitz, J S</creatorcontrib><creatorcontrib>Hansen, P R</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kristensen, K E</au><au>Zhu, H-J</au><au>Wang, X</au><au>Gislason, G H</au><au>Torp-Pedersen, C</au><au>Rasmussen, H B</au><au>Markowitz, J S</au><au>Hansen, P R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clinical Pharmacology &amp; Therapeutics</addtitle><date>2014-12</date><risdate>2014</risdate><volume>96</volume><issue>6</issue><spage>713</spage><epage>722</epage><pages>713-722</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>Clopidogrel is an oral antiplatelet prodrug, the majority of which is hydrolyzed to an inactive metabolite by hepatic carboxylesterase 1 (CES1). Most angiotensin‐converting enzyme inhibitors (ACEIs) are also metabolized by this enzyme. We examined the effects of ACEIs on clopidogrel bioactivation in vitro and linked the results with a pharmacoepidemiological study. In vitro, ACEIs inhibited CES1‐mediated hydrolysis of a model substrate, and trandolapril and enalapril increased formation of clopidogrel active metabolite. In 70,934 patients with myocardial infarction, hazard ratios for clinically significant bleeding in ACEI‐treated patients cotreated with or without clopidogrel were 1.10 (95% confidence interval (CI): 0.97–1.25, P = 0.124) and 0.90 (95% CI: 0.81–0.99, P = 0.025), respectively, as compared with patients who did not receive ACEIs. This difference was statistically significant (P = 0.002). We conclude that cotreatment with selected ACEIs and clopidogrel may increase the risk of bleeding. Combination of in vitro and pharmacoepidemiological studies may be a useful paradigm for assessment of drug–drug interactions. Clinical Pharmacology &amp; Therapeutics (2014); 96 6, 713–722. doi:10.1038/clpt.2014.183</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>25222620</pmid><doi>10.1038/clpt.2014.183</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-9236
ispartof Clinical pharmacology and therapeutics, 2014-12, Vol.96 (6), p.713-722
issn 0009-9236
1532-6535
language eng
recordid cdi_proquest_miscellaneous_1634498738
source Wiley-Blackwell Read & Publish Collection
subjects Aged
Angiotensin-Converting Enzyme Inhibitors - pharmacology
Biotransformation
Carboxylic Ester Hydrolases - physiology
Drug Interactions
Female
Hemorrhage - chemically induced
Humans
Male
Middle Aged
Myocardial Infarction - drug therapy
Platelet Aggregation Inhibitors - pharmacokinetics
Risk
Ticlopidine - adverse effects
Ticlopidine - analogs & derivatives
Ticlopidine - pharmacokinetics
title Clopidogrel Bioactivation and Risk of Bleeding in Patients Cotreated With Angiotensin-Converting Enzyme Inhibitors After Myocardial Infarction: A Proof-of-Concept Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T15%3A02%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clopidogrel%20Bioactivation%20and%20Risk%20of%20Bleeding%20in%20Patients%20Cotreated%20With%20Angiotensin-Converting%20Enzyme%20Inhibitors%20After%20Myocardial%20Infarction:%20A%20Proof-of-Concept%20Study&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Kristensen,%20K%20E&rft.date=2014-12&rft.volume=96&rft.issue=6&rft.spage=713&rft.epage=722&rft.pages=713-722&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1038/clpt.2014.183&rft_dat=%3Cproquest_cross%3E1634498738%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4903-99c8af94fb7135213eeee69b48b6985a57d26b334b813e7eaccbdc91b695f2da3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1634498738&rft_id=info:pmid/25222620&rfr_iscdi=true